Spots Global Cancer Trial Database for mcs110
Every month we try and update this database with for mcs110 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | NCT02807844 | Triple Negative... Pancreatic Carc... Melanoma Endometrial Car... | MCS110 PDR001 | 18 Years - | Novartis | |
| Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) | NCT02435680 | Advanced Triple... | MCS110 carboplatin gemcitabine | 18 Years - | Novartis | |
| MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) | NCT01643850 | Pigmented Villo... PVNS Giant Cell Tumo... GCCTS Tenosynovial Gi... GCTS | MCS110 Placebo | 12 Years - | Novartis | |
| Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | NCT03742349 | Triple Negative... | spartalizumab LAG525 NIR178 capmatinib MCS110 canakinumab | 18 Years - | Novartis | |
| MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) | NCT01643850 | Pigmented Villo... PVNS Giant Cell Tumo... GCCTS Tenosynovial Gi... GCTS | MCS110 Placebo | 12 Years - | Novartis | |
| MCS110 With BRAF/MEK Inhibition in Patients With Melanoma | NCT03455764 | Melanoma | MCS110 Dabrafenib Trametinib | 18 Years - | Dana-Farber Cancer Institute | |
| Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) | NCT02435680 | Advanced Triple... | MCS110 carboplatin gemcitabine | 18 Years - | Novartis | |
| Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | NCT02807844 | Triple Negative... Pancreatic Carc... Melanoma Endometrial Car... | MCS110 PDR001 | 18 Years - | Novartis | |
| A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases | NCT00757757 | Prostate Cancer Bone Metastases | MCS110 | 18 Years - | Novartis | |
| MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) | NCT01643850 | Pigmented Villo... PVNS Giant Cell Tumo... GCCTS Tenosynovial Gi... GCTS | MCS110 Placebo | 12 Years - | Novartis | |
| MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer | NCT03285607 | Breast Cancer Cancer of Breas... | MCS110 Doxorubicin Cyclophosphamid... Paclitaxel Bone marrow asp... Peripheral bloo... Tumor tissue | 18 Years - | Washington University School of Medicine | |
| Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | NCT03742349 | Triple Negative... | spartalizumab LAG525 NIR178 capmatinib MCS110 canakinumab | 18 Years - | Novartis | |
| MCS110 With BRAF/MEK Inhibition in Patients With Melanoma | NCT03455764 | Melanoma | MCS110 Dabrafenib Trametinib | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases | NCT00757757 | Prostate Cancer Bone Metastases | MCS110 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
